Plexxikon’s raf kinase inhibitor slows progression of polycystic kidney disease in preclinical models

Plexxikon’s raf kinase inhibitor slows progression of polycystic kidney disease in preclinical models

Ardeas MEK inhibitor RDEA119 effective in preclinical colitis models

Ardea Bioscience’s MEK inhibitor RDEA-119 has shown promising results in two different mouse models of colitis. Phase 1 data is expected in the second half of 2008